↓ Skip to main content

Similar HIV protection from four weeks of zidovudine versus nevirapine prophylaxis among formula-fed infants in Botswana

Overview of attention for article published in Southern African Journal of HIV Medicine, March 2018
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
36 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Similar HIV protection from four weeks of zidovudine versus nevirapine prophylaxis among formula-fed infants in Botswana
Published in
Southern African Journal of HIV Medicine, March 2018
DOI 10.4102/sajhivmed.v19i1.751
Pubmed ID
Authors

Kathleen M. Powis, Shahin Lockman, Gbolahan Ajibola, Michael D. Hughes, Kara Bennett, Jean Leidner, Oganne Batlang, Kerapetse Botebele, Sikhulile Moyo, Erik van Widenfelt, Joseph Makhema, Chipo Petlo, Haruna B. Jibril, Kenneth McIntosh, Max Essex, Roger L. Shapiro

Abstract

The World Health Organization HIV guidelines recommend either infant zidovudine (ZDV) or nevirapine (NVP) prophylaxis for the prevention of intrapartum mother-to-child HIV transmission (MTCT) among formula-fed infants. No study has evaluated the comparative efficacy of infant prophylaxis with twice daily ZDV versus once daily NVP in exclusively formula-fed HIV-exposed infants. Using data from the Mpepu Study, a Botswana-based clinical trial investigating whether prophylactic co-trimoxazole could improve infant survival, retrospective analyses of MTCT events and Division of AIDS (DAIDS) Grade 3 or Grade 4 occurrences of anaemia or neutropenia were performed among infants born full-term (≥ 37 weeks gestation), with a birth weight ≥ 2500 g and who were formula-fed from birth. ZDV infant prophylaxis was used from Mpepu Study inception. A protocol modification mid-way through the study led to the subsequent use of NVP infant prophylaxis. Among infants qualifying for this secondary retrospective analysis, a total of 695 (52%) infants received ZDV, while 646 (48%) received NVP from birth for at least 25 days but no more than 35 days. Confirmed intrapartum HIV infection occurred in two (0.29%) ZDV recipients and three (0.46%) NVP recipients (p = 0.68). Anaemia occurred in 19 (2.7%) ZDV versus 12 (1.9%) NVP (p = 0.36) recipients. Neutropenia occurred in 28 (4.0%) ZDV versus 21 (3.3%) NVP recipients (p = 0.47). Both ZDV and NVP resulted in low intrapartum transmission rates and no significant differences in severe infant haematologic toxicity (DAIDS Grade 3 or Grade 4) among formula-fed full-term infants with a birthweight ≥ 2500 g.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 36 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 14%
Student > Master 5 14%
Student > Bachelor 4 11%
Student > Ph. D. Student 3 8%
Student > Postgraduate 3 8%
Other 9 25%
Unknown 7 19%
Readers by discipline Count As %
Medicine and Dentistry 10 28%
Nursing and Health Professions 6 17%
Social Sciences 4 11%
Business, Management and Accounting 2 6%
Psychology 2 6%
Other 4 11%
Unknown 8 22%